Health Curium Announces Publication of [18F]DCFPyL Versus [18F]Fluoromethylcholine Results From European… James Pereira Jul 21, 2023 PARIS, July 21, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today the publication… Read More...
Health Curium Confirms No Supply Challenges in North America and Europe for its Eclipse Phase 3 Clinical… James Pereira Mar 14, 2023 <!-- Name:DistributionId Value:8788081 --> <!--… Read More...
Health Curium Announces New Indication for Ioflupane I 123 Injection in the U.S. James Pereira Nov 22, 2022 ST. LOUIS, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Curium, the world’s leading nuclear medicine company, announced today… Read More...
Health Curium Announces the Submission of its Marketing Authorization Application for [18F]-DCFPyL to the… James Pereira Jun 27, 2022 Submission follows the completion of Phase III PYTHON clinical trial of -DCFPyL for recurrent prostate cancer in Europe… Read More...
Health Curium Confirms No Supply Challenges of 177Lu-PSMA-I&T for ECLIPSE Trial James Pereira May 12, 2022 ST. LOUIS, May 12, 2022 (GLOBE NEWSWIRE) -- Curium confirmed today no supply challenges of 177Lu-PSMA-I&T for the… Read More...
Health Curium Announces Significant Increase in Detectnet™ (copper Cu 64 dotatate injection) Production… James Pereira Apr 19, 2022 ST. LOUIS, April 19, 2022 (GLOBE NEWSWIRE) -- Curium announced today that it will be increasing production capacity… Read More...
Health Curium Announces FDA Approval of a Generic Version of DaTscan™ (Ioflupane I 123 Injection) in the… James Pereira Apr 5, 2022 ST. LOUIS, April 05, 2022 (GLOBE NEWSWIRE) -- Curium announced today that its generic version of DaTscan (Ioflupane I… Read More...
Health Curium Acquires Austrian Radiopharmaceuticals Company IASON James Pereira Jun 1, 2021 Paris, May 31, 2021 (GLOBE NEWSWIRE) -- (Graz and Paris – June 1st, 2021) —Curium has successfully completed the… Read More...